China Resources Pharmaceutical Group Limited (abbrev. CHINARES PHARMA, HKEX: 03320) has released the unaudited financial statements of its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited (CR Pharmaceutical Holdings), for the six months ended 30 June 2026. The disclosure is a regulatory requirement linked to the subsidiary’s recent issuance of medium-term notes and corporate bonds in mainland China.

Financial Highlights for 1H 2026 (CR Pharmaceutical Holdings, PRC GAAP)

1. Revenue and Profitability • Operating revenue reached RMB 135.35 billion, up 2.0% from RMB 132.79 billion in 1H 2025. • Operating profit totalled RMB 6.40 billion, marginally down 2.4% year-on-year. • Net profit attributable to the parent company edged up 3.1% to RMB 1.82 billion, while total net profit slipped 1.3% to RMB 5.18 billion. • R&D expenses increased 14.6% to RMB 1.11 billion, indicating sustained investment in pipeline development.

2. Balance Sheet Strength • Total assets expanded 2.8% since end-2025 to RMB 294.45 billion. • Total liabilities rose 4.9% to RMB 180.44 billion, driven by: – Short-term borrowings climbing to RMB 44.69 billion (+9.7%). – Bonds payable increasing to RMB 16.72 billion (+64.0%), reflecting completion of the first and second tranches of 2026 medium-term notes and the first tranche of 2026 corporate bonds. • Owners’ equity remained broadly stable at RMB 114.01 billion (-0.2%), preserving a solid equity cushion with an equity ratio of 38.7%.

3. Cash Flow Trends • Net cash from operating activities fell 8.0% to RMB 1.45 billion, mainly due to higher outlays for goods and services. • Net cash used in investing activities narrowed to an outflow of RMB 0.53 billion versus RMB 5.38 billion outflow in 1H 2025, as investment recoveries outpaced new deployments. • Financing activities generated a net outflow of RMB 1.11 billion, reversing a RMB 4.74 billion inflow a year earlier, reflecting larger debt repayments despite RMB 7.70 billion raised from bond issues.

4. Parent-Level Performance (Holding Company Stand-Alone) • Stand-alone net profit surged to RMB 2.96 billion (1H 2025: RMB 0.26 billion), primarily on dividend income of RMB 3.09 billion from subsidiaries and associates. • Cash and cash equivalents rose to RMB 1.29 billion from RMB 0.61 billion at end-2025, supported by RMB 1.50 billion bond issuance.

Regulatory Context The publication supports CR Pharmaceutical Holdings’ ongoing mainland financing activities, including the completed issuance of two tranches of medium-term notes and the first tranche of corporate bonds in 2026. The financials are unaudited, prepared under PRC GAAP, and may be adjusted upon audit. They represent the subsidiary’s performance only and do not constitute the consolidated results of CHINARES PHARMA.

Investors are advised to interpret the data with caution and refer to subsequent audited disclosures for comprehensive insight.